PAISLEY: Deucravacitinib in SLE #RNL2023 Year in Review DEUC: oral TYK2i P2, 48w DBRCT in active SLE Primary endpt SRI4 at w32 - meets endpt, no dose response Phase 3 study results needed, promising results but JAK studies failed for SLE @RheumNow https://t.co/kKAKHnnG8i